Abstract
In silico classification of new compounds for certain properties is a useful tool to guide further experiments or compound selection. Interaction of new compounds with the efflux pump P-glycoprotein (P-gp) is an important drug property determining tissue distribution and the potential for drug-drug interactions. We present three datasets on substrate, inhibitor, and inducer activities for P-gp (n = 471) obtained from a literature search which we compared to an existing evaluation of the Prestwick Chemical Library with the calcein- AM assay (retrieved from PubMed). Additionally, we present decision tree models of these activities with predictive accuracies of 77.7 % (substrates), 86.9 % (inhibitors), and 90.3 % (inducers) using three algorithms (CHAID, CART, and C4.5). We also present decision tree models of the calcein-AM assay (79.9 %). Apart from a comprehensive dataset of P-gp interacting compounds, our study provides evidence of the efficacy of logD descriptors and of two algorithms not commonly used in pharmacological QSAR studies (CART and CHAID).
Keywords: P-glycoprotein, MDR1, Multidrug resistance, Calcein AM assay, QSAR, decision trees
Current Drug Metabolism
Title: Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein
Volume: 10 Issue: 4
Author(s): Felix Hammann, Heike Gutmann, Ursula Jecklin, Andreas Maunz, Christoph Helma and Juergen Drewe
Affiliation:
Keywords: P-glycoprotein, MDR1, Multidrug resistance, Calcein AM assay, QSAR, decision trees
Abstract: In silico classification of new compounds for certain properties is a useful tool to guide further experiments or compound selection. Interaction of new compounds with the efflux pump P-glycoprotein (P-gp) is an important drug property determining tissue distribution and the potential for drug-drug interactions. We present three datasets on substrate, inhibitor, and inducer activities for P-gp (n = 471) obtained from a literature search which we compared to an existing evaluation of the Prestwick Chemical Library with the calcein- AM assay (retrieved from PubMed). Additionally, we present decision tree models of these activities with predictive accuracies of 77.7 % (substrates), 86.9 % (inhibitors), and 90.3 % (inducers) using three algorithms (CHAID, CART, and C4.5). We also present decision tree models of the calcein-AM assay (79.9 %). Apart from a comprehensive dataset of P-gp interacting compounds, our study provides evidence of the efficacy of logD descriptors and of two algorithms not commonly used in pharmacological QSAR studies (CART and CHAID).
Export Options
About this article
Cite this article as:
Hammann Felix, Gutmann Heike, Jecklin Ursula, Maunz Andreas, Helma Christoph and Drewe Juergen, Development of Decision Tree Models for Substrates, Inhibitors, and Inducers of P-Glycoprotein, Current Drug Metabolism 2009; 10 (4) . https://dx.doi.org/10.2174/138920009788499021
DOI https://dx.doi.org/10.2174/138920009788499021 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy
Current Cancer Drug Targets Apoptotic Effect of Novel Benzimidazole Derivatives Bearing Pyridyl/Pyrimidinyl Piperazine Moiety
Anti-Cancer Agents in Medicinal Chemistry Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs
Current Molecular Medicine Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery NAD Metabolism and Functions: A Common Therapeutic Target for Neoplastic, Metabolic and Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Recent Trend for EGFR-Based and ALK-Based Targets: A Patent Analysis
Recent Patents on Anti-Cancer Drug Discovery CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Design and Development of Glutathione Conjugated Poly (d, l) lactide Nanocarriers for Delivery of Hydrophilic Fluorescent Marker across Blood Brain Barrier
Current Nanoscience Lack of Association between NOD2 rs3135500 and IL12B rs1368439 microRNA Binding Site SNPs and Colorectal Cancer Susceptibility in an Iranian Population
MicroRNA Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Yttrium-90 – Current Status, Expected Availability and Applications of a High Beta Energy Emitter
Current Radiopharmaceuticals Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design High Expression of miR-483-5p Predicts Chemotherapy Resistance in Epithelial Ovarian Cancer
MicroRNA Computational Methods for DNA-binding Protein and Binding Residue Prediction
Protein & Peptide Letters Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
Current Drug Targets Editorial [Hot Topic:Angiogenesis Agents(Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design The Antiproliferative and Pro-apoptotic Effects of Methoxyamine on Pediatric Medulloblastoma Cell Lines Exposed to Ionizing Radiation and Chemotherapy
Central Nervous System Agents in Medicinal Chemistry